«

»

Sanofi-GSK COVID-19 vaccine booster yields stronger result than Pfizer’s in trial

In a phase 2/3 study, Sanofi-GSK's next-generation COVID-19 vaccine booster resulted in 76.1 percent of participants seeing at least a tenfold increase in neutralizing antibody titers. Pfizer's booster and Sanofi-GSK's first-generation vaccine trailed behind at 63.2 percent and 55.3 percent, respectively, according to the June 13 press release. 

Read the full post at Becker's Hospital Review - Healthcare News
Vote This Post DownVote This Post Up (No Ratings Yet)
Explore the Archive